Home LiteratureArticle Details
PMID: 22429801 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

BMC cancer ·Vol. 12 ·2012-03-19 ·Pages 91

Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H

Abstract

The epithelial to mesenchymal transition (EMT) is a molecular process through which an epithelial cell undergoes transdifferentiation into a mesenchymal phenotype. The role of EMT in embryogenesis is well-characterized and increasing evidence suggests that elements of the transition may be important in other processes, including metastasis and drug resistance in various different cancers. Agilent 4 × 44 K whole human genome arrays and selected reaction monitoring mass spectrometry were used to investigate mRNA and protein expression in A2780 cisplatin sensitive and resistant cell lines. Invasion and migration were assessed using Boyden chamber assays. Gene knockdown of snail and slug was done using targeted siRNA. Clinical relevance of the EMT pathway was assessed in a cohort of primary ovarian tumours using data from Affymetrix GeneChip Human Genome U133 plus 2.0 arrays. Morphological and phenotypic hallmarks of EMT were identified in the chemoresistant cells. Subsequent gene expression profiling revealed upregulation of EMT-related transcription factors including snail, slug, twist2 and zeb2. Proteomic analysis demonstrated up regulation of Snail and Slug as well as the mesenchymal marker Vimentin, and down regulation of E-cadherin, an epithelial marker. By reducing expression of snail and slug, the mesenchymal phenotype was largely reversed and cells were resensitized to cisplatin. Finally, gene expression data from primary tumours mirrored the finding that an EMT-like pathway is activated in resistant tumours relative to sensitive tumours, suggesting that the involvement of this transition may not be limited to in vitro drug effects. This work strongly suggests that genes associated with EMT may play a significant role in cisplatin resistance in ovarian cancer, therefore potentially leading to the development of predictive biomarkers of drug response or novel therapeutic strategies for overcoming drug resistance.

MeSH Terms
Antineoplastic Agents/therapeutic use Cell Line, Tumor Cell Movement Cell Proliferation Cisplatin/therapeutic use Cohort Studies Drug Resistance, Neoplasm Epithelial-Mesenchymal Transition/physiology Female Gene Expression Profiling Humans Mass Spectrometry/methods Neoplasm Invasiveness Neoplasm Proteins/genetics,metabolism Ovarian Neoplasms/drug therapy,genetics,metabolism,pathology RNA, Messenger/metabolism Snail Family Transcription Factors Transcription Factors/genetics,metabolism
Chemicals
Antineoplastic Agents Neoplasm Proteins RNA, Messenger SNAI1 protein, human Snail Family Transcription Factors Transcription Factors Cisplatin
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Haslehurst Alexandria M
Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada.
Koti Madhuri
Dharsee Moyez
Nuin Paulo
Evans Ken
Geraci Joseph
Childs Timothy
Chen Jian
Li Jieran
Weberpals Johanne
Davey Scott
Squire Jeremy
Park Paul C
Feilotter Harriet
References (46)
46 references, click to expand
  1. Microarray analysis of gene expression during epithelial-mesenchymal transformation.
    Dev Dyn. 2005 Sep;234(1):132-42 PMID: 16010672
  2. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease.
    J Clin Invest. 2009 Jun;119(6):1438-49 PMID: 19487820
  3. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget.
    Oncotarget. 2010 Nov;1(7):651-61 PMID: 21317460
  4. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.
    Cancer Chemother Pharmacol. 2006 Sep;58(3):384-95 PMID: 16404635
  5. Genetics of kidney development.
    Curr Opin Nephrol Hypertens. 1996 May;5(3):282-7 PMID: 8737865
  6. Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
    Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S30-4 PMID: 19955911
  7. Analyzing real-time PCR data by the comparative C(T) method.
    Nat Protoc. 2008;3(6):1101-8 PMID: 18546601
  8. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.
    Cancer Metastasis Rev. 2009 Dec;28(3-4):335-44 PMID: 20012924
  9. Cancer early dissemination: cancerous epithelial-mesenchymal transdifferentiation and transforming growth factor β signalling.
    J Biochem. 2011 Jun;149(6):633-9 PMID: 21478191
  10. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
    PLoS Med. 2008 Dec 2;5(12):e232 PMID: 19053170
  11. Drug transporters of platinum-based anticancer agents and their clinical significance.
    Drug Resist Updat. 2011 Feb;14(1):22-34 PMID: 21251871
  12. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    J Clin Oncol. 2007 Feb 10;25(5):517-25 PMID: 17290060
  13. The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer.
    Gynecol Oncol. 2010 Feb;116(2):282-5 PMID: 19931138
  14. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
    Gynecol Oncol. 2010 May;117(2):170-6 PMID: 20132968
  15. Metastasis mechanisms.
    Biochim Biophys Acta. 2009 Dec;1796(2):293-308 PMID: 19683560
  16. The basics of epithelial-mesenchymal transition.
    J Clin Invest. 2009 Jun;119(6):1420-8 PMID: 19487818
  17. Snail blocks the cell cycle and confers resistance to cell death.
    Genes Dev. 2004 May 15;18(10):1131-43 PMID: 15155580
  18. Twist function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo.
    Dev Biol. 2002 Jul 15;247(2):251-70 PMID: 12086465
  19. Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern.
    Biomed Pharmacother. 2011 Feb;65(1):40-5 PMID: 21177063
  20. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression.
    Cancer Sci. 2007 Oct;98(10):1512-20 PMID: 17645776
  21. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
    Cancer Res. 2009 Jul 15;69(14):5820-8 PMID: 19584296
  22. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.
    Cell Death Dis. 2011 Jul 07;2:e179 PMID: 21734725
  23. Gene-expression profiling in epithelial ovarian cancer.
    Nat Clin Pract Oncol. 2008 Oct;5(10):577-87 PMID: 18648354
  24. Biomarkers for epithelial-mesenchymal transitions.
    J Clin Invest. 2009 Jun;119(6):1429-37 PMID: 19487819
  25. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.
    Dev Cell. 2008 Jun;14(6):818-29 PMID: 18539112
  26. Epithelial-mesenchymal transition in cancer development and its clinical significance.
    Cancer Sci. 2010 Feb;101(2):293-9 PMID: 19961486
  27. Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma.
    Hepatology. 2011 Nov;54(5):1690-706 PMID: 21748764
  28. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs.
    Crit Rev Immunol. 2009;29(3):241-54 PMID: 19538137
  29. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.
    Nat Rev Cancer. 2010 May;10(5):371-8 PMID: 20383179
  30. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1.
    J Cell Mol Med. 2011 Mar;15(3):691-700 PMID: 20219012
  31. Structural studies of interactions between anticancer platinum drugs and DNA.
    Prog Biophys Mol Biol. 1996;66(1):81-111 PMID: 9107133
  32. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
    Cancer Lett. 2011 Oct 1;309(1):11-8 PMID: 21676537
  33. Diagnostic markers for early detection of ovarian cancer.
    Clin Cancer Res. 2008 Feb 15;14(4):1065-72 PMID: 18258665
  34. Slug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling.
    Lab Invest. 2011 Mar;91(3):426-38 PMID: 21283078
  35. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes.
    Chem Biodivers. 2010 Mar;7(3):543-66 PMID: 20232326
  36. Chemotherapy: Current drugs still have potential in advanced ovarian cancer.
    Nat Rev Clin Oncol. 2010 Apr;7(4):191-3 PMID: 20354543
  37. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells.
    Oncogene. 2007 May 3;26(20):2860-72 PMID: 17072341
  38. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
    Am J Respir Crit Care Med. 2011 Apr 15;183(8):1071-9 PMID: 21037017
  39. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells.
    Stem Cells. 2009 Sep;27(9):2059-68 PMID: 19544473
  40. Molecular mechanisms of cisplatin resistance.
    Oncogene. 2012 Apr 12;31(15):1869-83 PMID: 21892204
  41. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression.
    J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34 PMID: 20490631
  42. Current clinical use of biomarkers for epithelial ovarian cancer.
    Curr Opin Oncol. 2010 Sep;22(5):492-7 PMID: 20613519
  43. EMT: when epithelial cells decide to become mesenchymal-like cells.
    J Clin Invest. 2009 Jun;119(6):1417-9 PMID: 19487817
  44. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
    Int J Gynaecol Obstet. 2001 Jan;72(1):55-60 PMID: 11146078
  45. Ovarian cancer: epidemiology, biology, and prognostic factors.
    Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 PMID: 10883018
  46. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it.
    Dev Dyn. 2005 Jul;233(3):706-20 PMID: 15937929
Article Info
Journal
BMC cancer
Abbr.
BMC Cancer
ISSN
1471-2407
Published
2012-03-19
Epub
2012-00-19
Pages
91
Language
English
Region
England
NLM ID
100967800
PMCID
PMC3342883
Subset
IM
Grants
Canadian Institutes of Health Research · Canada
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com